Tags

Type your tag names separated by a space and hit enter

REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome.
Sex Med 2016; 4(3):e135-44SM

Abstract

INTRODUCTION

Erectile dysfunction (ED) is prevalent in men with metabolic syndrome (MetS); therefore, it is important to characterize ED treatments in this population.

AIMS

To investigate the safety and effectiveness of vardenafil in men with ED and MetS in a clinical setting.

METHODS

REVITALISE is an international, prospective, single-arm, observational study in men with ED and MetS newly prescribed vardenafil. Vardenafil was prescribed at the discretion of the treating physician in line with the marketing authorization. Treatment effectiveness (International Index of Erectile Function [IIEF]) and health-related quality of life (Aging Males' Symptoms Scale) were assessed at treatment initiation, at an optional dose adjustment visit after approximately 4 weeks, and at the end of the observation period (approximately 12 weeks).

MAIN OUTCOME MEASURES

The primary outcome was an intraindividual improvement in erectile function (EF), defined as an increase of at least four points in the EF domain of the IIEF. Secondary outcomes included assessing normal EF (IIEF-EF score ≥ 26), mild ED (IIEF-EF score = 22-25), and health-related quality of life. Treatment-emergent adverse events were monitored.

RESULTS

In the intent-to-treat population (n = 1,832, mean age = 54.0 years, mean body mass index = 31.82 kg/m(2), Asian 36.8%, white 49.9%, 20.4% with severe ED, 75.6% with mild or moderate ED, 4.0% without ED), 82.4% reported an increase of at least four points in IIEF-EF score. Median IIEF-EF score increased from 15.0 (baseline) to 25.0 at 12 weeks (P < .0001). After treatment, 45.4% and 29.4% (intent-to-treat population) had normal EF and mild ED, respectively. Improvements in the sexual, psychological, and somatic subscales of the Aging Males' Symptoms Scale were found (P < .0001). Treatment-emergent adverse events were reported by 7.19% of patients; there were no serious adverse events related to vardenafil.

CONCLUSION

In a clinical setting, men with ED and MetS treated with vardenafil reported improvements in EF and health-related quality of life; and the safety profile of vardenafil was acceptable. REVITALISE demonstrates that vardenafil represents a good treatment option for men with ED and MetS.

Authors+Show Affiliations

Chairman, Department of Surgery, SBH Health System, Bronx, NY; Professor of Clinical Urology, Cornell University, Ithaca, NY, USA. Electronic address: rshabsigh@gmail.com.Bayer Pharma AG, Berlin, Germany.No affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

27151768

Citation

Shabsigh, Ridwan, et al. "REVITALISE: a Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome." Sexual Medicine, vol. 4, no. 3, 2016, pp. e135-44.
Shabsigh R, Mattern A, REVITALISE Study Group. REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. Sex Med. 2016;4(3):e135-44.
Shabsigh, R., & Mattern, A. (2016). REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. Sexual Medicine, 4(3), pp. e135-44. doi:10.1016/j.esxm.2016.03.027.
Shabsigh R, Mattern A, REVITALISE Study Group. REVITALISE: a Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. Sex Med. 2016;4(3):e135-44. PubMed PMID: 27151768.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - REVITALISE: A Large Observational Study Assessing the Safety and Effectiveness of Vardenafil in Men With Erectile Dysfunction and Metabolic Syndrome. AU - Shabsigh,Ridwan, AU - Mattern,Andreas, AU - ,, Y1 - 2016/04/14/ PY - 2015/11/25/received PY - 2016/02/24/revised PY - 2016/03/15/accepted PY - 2016/5/7/entrez PY - 2016/5/7/pubmed PY - 2016/5/7/medline KW - Erectile Dysfunction KW - Metabolic Syndrome KW - Phosphodiesterase Type 5 Inhibitor KW - Vardenafil SP - e135 EP - 44 JF - Sexual medicine JO - Sex Med VL - 4 IS - 3 N2 - INTRODUCTION: Erectile dysfunction (ED) is prevalent in men with metabolic syndrome (MetS); therefore, it is important to characterize ED treatments in this population. AIMS: To investigate the safety and effectiveness of vardenafil in men with ED and MetS in a clinical setting. METHODS: REVITALISE is an international, prospective, single-arm, observational study in men with ED and MetS newly prescribed vardenafil. Vardenafil was prescribed at the discretion of the treating physician in line with the marketing authorization. Treatment effectiveness (International Index of Erectile Function [IIEF]) and health-related quality of life (Aging Males' Symptoms Scale) were assessed at treatment initiation, at an optional dose adjustment visit after approximately 4 weeks, and at the end of the observation period (approximately 12 weeks). MAIN OUTCOME MEASURES: The primary outcome was an intraindividual improvement in erectile function (EF), defined as an increase of at least four points in the EF domain of the IIEF. Secondary outcomes included assessing normal EF (IIEF-EF score ≥ 26), mild ED (IIEF-EF score = 22-25), and health-related quality of life. Treatment-emergent adverse events were monitored. RESULTS: In the intent-to-treat population (n = 1,832, mean age = 54.0 years, mean body mass index = 31.82 kg/m(2), Asian 36.8%, white 49.9%, 20.4% with severe ED, 75.6% with mild or moderate ED, 4.0% without ED), 82.4% reported an increase of at least four points in IIEF-EF score. Median IIEF-EF score increased from 15.0 (baseline) to 25.0 at 12 weeks (P < .0001). After treatment, 45.4% and 29.4% (intent-to-treat population) had normal EF and mild ED, respectively. Improvements in the sexual, psychological, and somatic subscales of the Aging Males' Symptoms Scale were found (P < .0001). Treatment-emergent adverse events were reported by 7.19% of patients; there were no serious adverse events related to vardenafil. CONCLUSION: In a clinical setting, men with ED and MetS treated with vardenafil reported improvements in EF and health-related quality of life; and the safety profile of vardenafil was acceptable. REVITALISE demonstrates that vardenafil represents a good treatment option for men with ED and MetS. SN - 2050-1161 UR - https://www.unboundmedicine.com/medline/citation/27151768/REVITALISE:_A_Large_Observational_Study_Assessing_the_Safety_and_Effectiveness_of_Vardenafil_in_Men_With_Erectile_Dysfunction_and_Metabolic_Syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S2050-1161(16)00059-3 DB - PRIME DP - Unbound Medicine ER -